The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2 receptor subtype
A. Espanol, A. Salem, M. Di Bari, I. Cristofaro, Y. Sanchez, A. Tata, M. E. Sales
The paper investigates the effect of combining paclitaxel with muscarinic agonists on triple negative breast tumors, finding that M2 receptor activation reduces cell viability and tumor progression.
bioRxiv · Nov 29, 2019Pharmacology & Toxicology